key: cord-0729092-bcs474g4
authors: Montastruc, Jean-Louis; Lafaurie, Margaux; de Canecaude, Claire; Montastruc, François; Bagheri, Haleh; Durrieu, Geneviève; Sommet, Agnès
title: COVID-19 vaccines: a perspective from social pharmacology
date: 2021-05-28
journal: Therapie
DOI: 10.1016/j.therap.2021.05.010
sha: 798e28048cfa9d6b3cb942a5e0680d2522f39897
doc_id: 729092
cord_uid: bcs474g4

Social Pharmacology is a branch of clinical pharmacology, which depicts relationships between society and drugs and in particular factors, reasons, social consequences of drug use as well as representations of drugs in the society. Recent development and marketing of coronavirus disease 2019 (COVID-19) vaccines raises a number of questions of Social Pharmacology: are vaccines drugs like any other? What is their perception at the individual, population and societal levels? How do individuals perceive the risks and benefits of these vaccines? What is the perception at the societal level? What is the individual and societal acceptability of these vaccines during a pandemic? All these questions are discussed in the light of recent data. A number of proposals, both at the individual and at the collective or population level, are formulated to help solve these problems of social pharmacology.

Several vaccines are being developed as part of the COVID-19 pandemic. The first vaccines to be marketed were the Pfizer tozinameran Comirnaty ® [1] and Moderna [2] messenger RNA (mRNA) vaccines, followed by the adenovirus vaccines from Astra Zeneca Vaxzevria ® [3] and Janssen (Johnson and Johnson) [4] . Today, Russian vaccine, another adenovirus vaccine, is not marketed in Europe or United States [5] . Other reviews in this special issue have discussed the data from clinical trials [6] as well as pharmacovigilance [7] and pharmacoepidemiological [8] studies. However, After a brief review of purposes and objectives of social pharmacology, this review will discuss some of the major issues in social pharmacology as applied to COVID-19 vaccines, without seeking to be exhaustive.

A short reflection on pharmacology, as a scientific and medical discipline, clearly shows its evolution from a pure biological and fundamental science (molecular pharmacology, cellular pharmacology, experimental pharmacology) to a clinical (clinical pharmacology) and an epidemiological discipline (pharmacovigilance, pharmacoepidemiology) and now to a social science: social pharmacology ( Fig.   1 ).

Social pharmacology is the study of interactions between drugs and society. Like pharmacology with its two branches, pharmacokinetics and pharmacodynamics, social pharmacology has two aspects: the first is "social pharmacokinetics", i.e. investigation of drug "metabolism" by society, and the second "social pharmacodynamics", which studies changes in human behaviour in society as a result of drug use (Fig. 2) .

Social pharmacology studies can be summarized into five main themes [9, 10] Finally, as said by Gilles Bardelay, the founder of "La Revue Prescrire", social pharmacology can be defined as a view on "Drugs, differently".

All actors of the private (before marketing authorisation) or public (after marketing authorisation) drug life do participate to social pharmacology: academic and industrial researchers, pharmaceutical industry, health agencies, control and authorisation systems, health professionals, university members, lawyers, patients of course and finally the media, journalists and consumer press [9, 10] .

All these data on Social Pharmacology are highly relevant to COVID-19 vaccines. This review aimed to discuss all aspect of social pharmacology in the field of COVID-19 vaccines.

First of all, vaccines correspond to the definition of drugs "by function", i.e. products with preventive properties and/or modifying body's organic functions. Thus, vaccines have been studied and developed in the same way as all other drugs, including phase I, II, III clinical pharmacology trials.

In this respect, the very rapid development of COVID-19 vaccines (within a few months) for a new and previously totally unknown disease should be congratulated. This scientific and technological achievement should be underlined and classified in the "benefits" column for patients and society. However, daily observations and analyses of social pharmacology show that this benefit part is still badly perceived, minimised or even forgotten by patients and society. This is because the societal pressure of risk(s) is greater than the weight of benefit(s) alone. Fig. 3 illustrates this imbalance in relation to drugs in general. This Fig. 3 must be considered with even more acuity and reality for vaccines compared to other drugs.

However, vaccines are special products within drugs. On the one hand, they are administered to healthy subjects (often infants or children) to prevent a hypothetical disease. This disease is generally unknown or forgotten by the general public (tetanus, diphtheria, poliomyelitis...) which leads to a partial, biased and often false vision of the problem by non-health professionals (and sometimes even by some health professionals themselves). On the other hand, benefits of vaccination are not only individual (for vaccinated populations) but also population-based (for unvaccinated subjects). People often poorly understand societal importance of this herd immunity. However, many dispute this notion of collective benefit and herd immunity, pointing out that reasoning in terms of benefits-risks balance only makes sense collectively, since the patient who will suffer from adverse drug reactions will not be "saved" by the vaccine. Accordingly, vaccine hesitancy rose in France Clearly, much remains to be done to improve the individual and societal acceptability of vaccines [12] .

Pharmacovigilance data concerning adverse drug reactions of COVID-19 vaccines are discussed elsewhere in this issue [7] . use of these vaccines. This is an example of what has been discussed above: social pharmacodynamics, or how drug modify behaviour of groups in society. It is also noteworthy to consider that vaccine hesitancy is politically polarized in France, with the highest hesitancy among people lose to far right and far left parties [13] , while in the Anglo-Saxon world, hesitancy is mostly associated with conservative ideology or republican partisan identity.

The pharmacovigilance monitoring carried out by the French regional pharmacovigilance between occurrence and causality (or association). To some extent, could this high level of transparency not be detrimental to the acceptability of these vaccines?

In fact, people and unfortunately also the vast majority of health professionals do not know how to distinguish between harms (adverse drug reactions) and risks. Risk is a probability and harms a source of damage, in this case adverse effects. Obviously, health professionals have great difficulty in quantifying the individual risk for a specific patient. This often leads them to refuse the drug (here the vaccine) altogether, stop prescribing it at all and turn to another alternative. This is the distinction between individual danger and collective risk, which is impossible to solve by the treating physician in front of his individual patient.

The issue of vaccine availability is discussed daily and widely in the media. The problem of relative shortage of vaccines, at least at beginning of the vaccination campaign (first quarter of 2021), regardless of production difficulties, has been widely discussed. The question of licence buy-back by states was also largely questioned. It is recalled here without being discussed further in this article.

Newspapers only consider "rich" countries in order to find out the arrival times and the distribution of the different vaccines. They forget the problem of the globalisation of drugs. In fact, we observe that the concerns of the media and governments relate solely to their countries, recalling the adage that was previously developed for HIV drugs "patients are in the South and drugs in the J o u r n a l P r e -p r o o f 8 All these data, comments and reflections clearly indicate that drugs in general and vaccines in particular are no longer today just a scientific and medical object but also a social (societal) and

political topic [14] . Council of Europe has also made a number of proposals in the field [15] .

These actions and trainings to be developed are the only means to allow our fellow citizens to understand the medical and societal stakes of the current vaccination campaign against Covid-19 as well as those which will undoubtedly occur in the future. In this sense, social pharmacology is an important part of rational drug evaluation (i.e. clinical pharmacology). The skills of social pharmacology should be taken into account and integrated into drug policies in all countries. The health of our citizens is at stake.

Authors have no competing interest to declare

The work was performed during the university research time of the authors. There were no funding sources. The authors certify that they have not received any funding from any institution, including personal relationships, interests, grants, employment, affiliations, patents, inventions, honoraria, consultancies, royalties, stock options/ownership, or expert testimony for the last 48 months. 

Risks

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous primeboost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Efficacy of Covid-19 vaccines: from clinical trials to real life

French organization for the Pharmacovigilance of COVID-19 vaccines: a major challenge

Evaluation of Covid-19 vaccines: pharmacoepidemiological aspects

Social pharmacology: a new topic in clinical pharmacology

Medicamentation" of society, nondiseases and non-medications: a point of view from social pharmacology

Vaccine hesitancy and coercion: all eyes on France

How to improve vaccine acceptability (evaluation, pharmacovigilance, communication, public health, mandatory vaccination, fears and beliefs)

The French public's attitudes to a future COVID-19 vaccine: The politicization of a public health issue

Is the drug a scientific, social or political object?

Covid-19 vaccines: ethical, legal and practical considerations. Resolution 2361